NR1H4 and Hepatic fibrosis: Research indicates that INT-767, an agonist for both FXR and TGR5, can improve metabolic control, reduce liver fibrosis, and decrease inflammation in animal models of liver disease (Comeglio et al., 2018; Jadhav et al., 2018; Roth et al., 2018).